

## Summit on Anti-SARS-CoV-2 Antibodies for Treatment and Prevention of COVID-19: Lessons Learned and Remaining Questions

**Date & Time:** June 15, 2021, 11:00 AM – 4:00 PM EDT **Broadcast Live at:** [videocast.nih.gov/watch=42078](https://videocast.nih.gov/watch=42078)

No Registration Required – Open for Public Viewing

**Purpose:** To summarize current knowledge and lessons learned on clinically relevant anti-SARS-CoV-2 antibodies for the treatment and/or prevention of COVID-19 and to identify key unanswered scientific questions to catalyze antibody clinical development and implementation.

### Agenda

#### 11:00 AM – 11:15 AM **Introductory Comments**

- Dr. Francis S. Collins – Director, National Institutes of Health
- Dr. Janet Woodcock – Acting Commissioner, US Food and Drug Administration
- Dr. Anthony S. Fauci – Director, National Institute of Allergy and Infectious Diseases

#### 11:15 AM – 12:30 PM **State of the Science Presentations**

- *Convalescent plasma and hyperimmune globulin:* Dr. Peter Marks – US Food and Drug Administration
- *Antibodies for COVID-19 prevention:* Dr. Myron S. Cohen – University of North Carolina at Chapel Hill
- *Antibodies for COVID-19 treatment:*
  - Dr. Kara Chew – University of California, Los Angeles
  - Dr. Jens Lundgren – Rigshospitalet, University of Copenhagen
- *Mutations/variants of concern:* Dr. Bette Korber – Los Alamos National Laboratory

#### 12:30 PM – 1:30 PM **Session I: Mechanisms of Action of Functional Antibodies that Neutralize SARS-CoV-2 and/or Eliminate SARS-CoV-2 Infected Cells**

- *Presenter:* Dr. Erica O. Saphire – La Jolla Institute for Immunology
- *Moderator:* Dr. Adrian McDermott – National Institute of Allergy and Infectious Diseases
- *Panelists:*
  - Dr. Christopher Barnes – Stanford University
  - Dr. Michael Diamond – Washington University in St. Louis
  - Dr. David Montefiori – Duke University
  - Dr. Penny Moore – University of the Witwatersrand
  - Dr. Rachel Liberatore – RenBio
  - Dr. Laura Walker – Adagio Therapeutics

1:30 PM – 1:45 PM **-Break-**

**1:45 PM – 2:45 PM**

**Session II: Preclinical Delivery, Pharmacology, and Efficacy of Anti-SARS-CoV-2 Antibodies**

- *Presenter:* Dr. Ralph Baric – University of North Carolina at Chapel Hill
- *Moderator:* Dr. Connie Schmaljohn - National Institute of Allergy and Infectious Diseases
- *Panelists:*
  - Dr. Christopher Ellis – US Food and Drug Administration
  - Dr. Tom Hope – Northwestern University
  - Dr. Kevin Saunders – Duke University
  - Dr. Skip Virgin – Vir Biotechnology
  - Dr. Emmie de Wit - National Institute of Allergy and Infectious Diseases

**2:45 PM – 3:45 PM**

**Session III: Real World Clinical Use of Anti-SARS-CoV-2 Antibodies**

- *Presenter:* Dr. Katharine Bar – University of Pennsylvania
- *Moderator:* Dr. Rajesh Gandhi – Massachusetts General Hospital
- *Panelists:*
  - Dr. Ada Adimora – University of North Carolina at Chapel Hill
  - Dr. Judith Currier – University of California Los Angeles
  - Dr. Fred Korley – University of Michigan
  - Dr. Meagan O’Brien – Regeneron
  - Dr. John Redd – HHS Office of the Assistant Secretary for Preparedness and Response
  - Dr. Mark Williams – Lilly

**3:45 PM – 4:00 PM**

**Wrap Up and Closing Comments**

- Dr. Adrian McDermott – National Institute of Allergy and Infectious Diseases
- Dr. Connie Schmaljohn - National Institute of Allergy and Infectious Diseases
- Dr. Rajesh Gandhi – Massachusetts General Hospital
- Dr. Francis S. Collins – Director, National Institutes of Health